Laurikka-Routti M
City Maternity Hospital, Helsinki, Finland.
Obstet Gynecol. 1992 Nov;80(5):855-9.
To study the changes in serum lipids, serum chemistry, blood pressure, and body weight in long-term users of subcutaneous contraceptive implants releasing the progestin ST 1435.
The study was done in the outpatient clinic of the City Maternity Hospital, Helsinki, Finland. Subdermal implants releasing the progestin ST 1435 were inserted in 30 women for 2 years of use. Healthy women aged 19-35 used the implants for contraception. Measurements of body weight and blood pressure were made and blood samples for lipid analysis (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides) and serum chemistry were taken before insertion of the implants and every 6 months thereafter until removal. Results are reported for 30 subjects after 6 months of use, 25 subjects after 12 months, 13 after 18 months, and 12 after 24 months.
Blood pressure and serum chemistry, ie, liver enzymes and electrolytes, remained unchanged. Slight weight gain occurred, but was not statistically significant. No statistically significant changes were found in lipids or lipid ratios when comparing the values during use of the implant with the pre-treatment values.
The progestin ST 1435, used parenterally for contraception or progestin therapy, had no adverse effects on serum lipids, blood pressure, or body weight, which are known to be risk factors for coronary artery disease. The steroid had no effects on serum chemistry determinations in long-term use.
研究长期使用释放孕激素ST 1435的皮下避孕植入剂的使用者的血脂、血清化学指标、血压和体重的变化。
该研究在芬兰赫尔辛基市妇产医院的门诊进行。将释放孕激素ST 1435的皮下植入剂植入30名女性体内，使用2年。年龄在19 - 35岁的健康女性使用该植入剂进行避孕。在植入植入剂前以及此后每6个月进行一次体重和血压测量，并采集血样进行血脂分析（总胆固醇、高密度脂蛋白胆固醇、低密度脂蛋白胆固醇和甘油三酯）以及血清化学指标检测，直至取出植入剂。报告了使用6个月后的30名受试者、12个月后的25名受试者、18个月后的13名受试者以及24个月后的12名受试者的结果。
血压和血清化学指标，即肝酶和电解质，保持不变。体重略有增加，但无统计学意义。将植入剂使用期间的值与治疗前的值进行比较时，血脂或血脂比值未发现有统计学意义的变化。
经肠胃外途径用于避孕或孕激素治疗的孕激素ST 1435，对血脂、血压或体重没有不良影响，而这些已知是冠状动脉疾病的危险因素。该类固醇在长期使用中对血清化学指标测定没有影响。
